CD19 and lymphoma: CAR-21 NK cells showed similar immunophenotypic profiles compared to CAR-15 NK cells, while IL-21 engineered CAR-NK cells exhibited significantly increased persistence and superior anti-tumor efficacy against CD19+ Raji lymphoma cells both in vitro and in vivo.